BOSTON (Reuters) - Boehringer Ingelheim said on Saturday it plans to initiate a late-stage clinical trial of its experimental hepatitis C treatment following promising results from earlier studies. The company announced final data from a mid-stage trial of its treatment regimen which showed that 69 percent of patients in the study were free of the virus 12 and 24 weeks following the end of treatment. Hepatitis C is a blood-borne infectious disease of the liver that can lead to liver failure and transplant. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment